Long, I agree that they seems Zenith/RVX  like BMS would be  great fit to their Portfolio, that being said RVX/Zenith woudl be a great fir for any BP.  If Epigenetics is the next CRISPR for novel /futuristic medicine than one of the BP should take a gamble at a buyout or large Partnership with both co's  

Constellation Phara has alrady been taken out,  so you would think another BP would be interested in both Zenith and RVX , Just has to be at the right price.   That could be the disconnect